Avendus Capital advises Kapiva on its USD 57 million fundraise led by 360 One & Vertex Growth

We set out to build consumer trust with evidence, not claims. This funding represents confidence in our vision to make Ayurveda the preferred choice for holistic wellness. The combination of availability in over 40,000 stores and on leading online marketplaces, along with clinical trials on Dia Free and Shilajit Gold, reflects our commitment to products that are both accessible and proven. Our research-led approach guides every formulation, from ingredient selection to validation, so that consumers can choose Ayurveda with confidence.

The wellness industry is experiencing a fundamental shift toward preventive healthcare, and Kapiva’s evidence-based approach, illustrated by clinical trials on products like Dia Free and Shilajit Gold, sets them apart. Their 40,000-store presence and 80% year-on-year growth underlines the scale of what Kapiva’s team has achieved, making this an ideal partnership for us

India's wellness heritage has global appeal, and Kapiva’s research-driven formulations have global potential and appeal. We are excited to support Kapiva team’s vision of making clinically validated Ayurvedic products, already leading in categories like diabetes care and fitness, accessible to consumers worldwide.

Proud to support Ameve and the Kapiva team on this milestone fundraise, set to fuel their next phase of growth and strengthen their leadership in the fast-growing health and wellness sector. Driven by sharp execution and bold innovation, Kapiva is reshaping the nutraceuticals space by combining modern Ayurveda with deep consumer insights. Category-defining brands like Kapiva are setting new benchmarks and attracting top-tier investors eager to back the next wave of consumer leaders.